Repros Therapeutics (formerly Zonagen) zeroes in on reproductive health. The pharmaceutical firm develops small-molecule drugs to treat hormonal and reproductive system disorders. Its lead candidate, Proellex, was in clinical trials as a possible therapy for uterine fibroids (benign tumors within the uterus) and for anemia associated with uterine fibroids, but the company suspended Proellex trials in 2009 due to safety concerns. Repros' second candidate Androxal may treat testosterone deficiencies in men, particularly in relation to the drug's effects on fertility. The company has been strapped for cash, and consequently exploring strategic options including raising funds through a public offering.